Comparison

MOTS-c vs
SS-31

Both appear in mitochondrial research, but that describes a different relationship to mitochondria for each peptide.

Short answerCompound research · 5 min read · Updated 21 Nov 2026

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA; SS-31, or elamipretide, is a synthetic four-amino-acid peptide that binds cardiolipin. FDA staff found no published study that gave MOTS-c to people in their 2026 review. Elamipretide’s randomised trial compared it with placebo, not with MOTS-c, in 12 patients with Barth syndrome.

Key takeaways

  • The human MOTS-c studies discussed here measured levels of the peptide the body makes, rather than giving participants MOTS-c.
  • The randomized elamipretide trial in 12 patients with Barth syndrome and its uncontrolled extension answer different questions.
  • HHS names MOTS-c in a draft, non-binding compounding policy; FDA staff reported that neither its free base nor its acetate was an ingredient in an FDA-approved drug.
  • WADA names MOTS-c in S4.4.1 and prohibits it at all times; SS-31 and elamipretide are not named on the 2026 or 2027 List, and we draw no sport-status conclusion of our own.

01MOTS-c vs SS-31 in one table

QuestionMOTS-cSS-31 (elamipretide)
Identity16-amino-acid peptide encoded in the mitochondrial 12S rRNA region.Synthetic four-amino-acid peptide that binds cardiolipin, a lipid in the inner mitochondrial membrane.
Evidence tierT2 for measurements of natural levels in people; T3 for animal experiments and T4 for cell studies. These animal and cell studies are not evidence of an effect in people.T1 for the randomized portion of TAZPOWER; T2 for its uncontrolled extension. Research-grade material labelled SS-31 is not the formulation studied.
Human dataReynolds et al. (2021) measured natural levels in muscle and blood in 10 young men who cycled. FDA staff’s July 2026 review found no published study that gave MOTS-c to people.TAZPOWER (2021 journal issue) measured six-minute walk distance and fatigue as its primary endpoints in 12 patients with Barth syndrome. The trial compared elamipretide with placebo, not MOTS-c. Research-grade material labelled SS-31 is not the formulation studied.
United StatesFDA staff reported that neither the free base nor acetate was an ingredient in an FDA-approved drug. HHS names MOTS-c in its October 2026 draft, non-binding interim compounding policy.FDA granted accelerated approval to Forzinity to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, based on a change in knee extensor strength in an uncontrolled extension. Research-grade material labelled SS-31 is not that formulation.
United KingdomThe emc medicines database returned no results for MOTS-c (21 November 2026); it is not the full UK register.The emc medicines database returned no results for elamipretide or Forzinity (21 November 2026); it is not the full UK register.
AustraliaThe TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” MOTS-c has no entry by name in the October 2026 Poisons Standard; we draw no scheduling conclusion of our own.We found no entry for SS-31 or elamipretide in the October 2026 Poisons Standard; we draw no scheduling conclusion of our own.
SportNamed in WADA class S4.4.1, metabolic modulators, and prohibited at all times under both the 2026 and 2027 Lists.SS-31 and elamipretide are not named on either List; we draw no sport-status conclusion of our own.

02What differs at the molecular level?

If you searched “mots c vs ss 31”, start with what the term mitochondrial describes in each case.

MOTS-c: where the instructions are

The instructions for this 16-amino-acid peptide sit in a short stretch of mitochondrial DNA in the 12S rRNA region.

SS-31: what the peptide binds

Elamipretide is a synthetic peptide of four amino acids. The FDA label describes it as a binder of cardiolipin, a lipid in the inner mitochondrial membrane.

They share a research setting, not a molecular identity. Where a peptide is encoded and what another peptide binds are two different facts. Neither tells you how the two would compare on the same measure in the same people.

03What did the studies actually compare?

MOTS-c. In 2021, Reynolds and colleagues measured the body’s own MOTS-c in muscle and blood from 10 young men who cycled (T2). The researchers did not give the men the peptide. In the same paper, a separate experiment measured treadmill running time and distance in mice (T3; the middle-aged groups had 10 mice each, and the older groups had 18 and 19). The mouse experiment is not evidence of an effect in people. For more on the difference between natural levels and an administered compound, see the MOTS-c research guide.

Elamipretide. In TAZPOWER, published in the 2021 journal issue, each of the 12 patients with Barth syndrome received both elamipretide and placebo in separate periods, in a randomized sequence (T1). The FDA label says elamipretide was not superior to placebo on six-minute walk distance or the trial’s fatigue score. The label places the knee-strength finding in the later open-label extension, which 10 patients entered and which did not have a concurrent placebo group (T2). Research-grade material labelled SS-31 is not the formulation studied. Not medical advice.

04How did the U.S. regulatory paths differ?

  1. 19 September 2025FDA grants accelerated approval to Forzinity

    The indication is to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. FDA based the decision on a change in knee extensor strength, an intermediate measure, and required a confirmatory trial to verify patient benefit. Research-grade material labelled SS-31 is not the approved formulation. Not medical advice.

  2. July 2026FDA staff and its advisory committee differ on MOTS-c

    FDA staff recommended against listing the free base and acetate for section 503A compounding. HHS records that the committee voted in favour of listing both forms. An advisory recommendation is not a listing.

  3. 30 October 2026The Federal Register publishes notice of the HHS draft

    The draft, non-binding interim policy names MOTS-c in Appendix A and describes when HHS does not intend to enforce against certain compounders. The notice says the draft “is not binding on HHS or the public”.

These records concern different decisions: one about a specific finished formulation and labelled population, the other about enforcement discretion for compounding. Neither determines what WADA lists. The 2026 Prohibited List is in force on 21 November 2026; the 2027 List comes into force on 1 January 2027.

05What we don't know

The human studies described here do not compare MOTS-c with elamipretide. Measuring a peptide already in the body cannot tell you what happens when it is given to someone. A placebo comparison for elamipretide in patients with Barth syndrome cannot answer that question for MOTS-c. These data do not support a verdict on which peptide is better.

Neither a study nor a regulatory record establishes what is in a particular research vial. For that narrower question, read the certificate of analysis, or COA, for the specific lot.

1
Match the lot

Check that the identifier on the report matches the identifier on the vial.

2
Find the identity result

Look for the named peptide and the method used to identify it. A purity percentage alone does not distinguish MOTS-c from elamipretide.

3
Read purity separately

Check what method produced the purity result. See how to read a COA for the difference between identity and purity.

This is a plain-English summary of public records and studies, dated 21 November 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. [MOTS-c free base and acetate briefing]. Pharmacy Compounding Advisory Committee briefing, July 2026, pp. 7–11, 20, 30–33. www.fda.gov/media/193347/download
  2. U.S. Food and Drug Administration. [Forzinity prescribing information]. FDA label, September 2025, sections 1, 11, 12 and 14. www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000…
  3. U.S. Food and Drug Administration. [Forzinity accelerated approval and confirmatory trial requirement]. FDA announcement, 19 September 2025. www.fda.gov/news-events/press-announcements/fda-grants-accel…
  4. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Draft policy with Appendices A and B, October 2026; read on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov refuses automated readers). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  5. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice, 91 FR 68526, 30 October 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  6. World Anti-Doping Agency. 2026 Prohibited List. International Standard, section S4.4.1. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  7. World Anti-Doping Agency. 2027 Prohibited List and Summary of Major Modifications and Explanatory Notes. International Standard, section S4.4.1, and companion notes; List in force 1 January 2027. www.wada-ama.org/en/resources/2027-prohibited-list
  8. Australian Federal Register of Legislation. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, F2026L01327. Instrument, full text searched 21 November 2026. www.legislation.gov.au/F2026L01327/asmade/2026-09-30/text/or…
  9. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 September 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au does not respond to automated readers). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  10. Electronic medicines compendium (emc). Searches for MOTS-c, elamipretide and Forzinity: “No search results” for each (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=elamipretide
  11. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c measurements in human exercise and experiments in mice and cells]. Nature Communications, 2021;12:470. PMID 33473109. www.nature.com/articles/s41467-020-20790-0
  12. Thompson WR, Hornby B, Manuel R, et al. [TAZPOWER randomized crossover trial and open-label extension]. Genetics in Medicine, 2021;23:471–478. Online 20 October 2020. PMID 33077895. pmc.ncbi.nlm.nih.gov/articles/PMC7935714/

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is SS-31 another name for MOTS-c?

No. SS-31 is elamipretide, a synthetic four-amino-acid peptide that binds cardiolipin. MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region.

Did the Reynolds study give MOTS-c to people?

No. Reynolds and colleagues measured the body’s own MOTS-c in muscle and blood in 10 young men who cycled. That is a measurement of natural levels, not a test of an administered peptide.

Did TAZPOWER compare SS-31 with MOTS-c?

No. TAZPOWER compared elamipretide with placebo in 12 patients with Barth syndrome. Its two primary measures were walking distance and a fatigue score. Research-grade material labelled SS-31 is not the formulation studied.

Does the WADA List name both peptides?

WADA names MOTS-c in S4.4.1 and prohibits it at all times. SS-31 and elamipretide are not named in the 2026 or 2027 Lists; we draw no sport-status conclusion of our own.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page